Coccidioidomycosis in persons infected with HIV-1

Annals of the New York Academy of Sciences

Volumn 1111, Issue , 2007, Pages 336-342

  Ampel, Neil M ^a  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

Coccidioidomycosis; HIV 1; Human

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; DRUG METABOLITE; EFAVIRENZ; FLUCONAZOLE; HYDROXYITRACONAZOLE; INDINAVIR; ITRACONAZOLE; LOPINAVIR; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TRIAZOLE DERIVATIVE; VORICONAZOLE;

CD4 LYMPHOCYTE COUNT; CELL CULTURE; COCCIDIOIDOMYCOSIS; CONFERENCE PAPER; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MYCOPLASMA PNEUMONIA; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; RECURRENT DISEASE; RISK FACTOR; SEROLOGY; THORACIC CAVITY; TREATMENT DURATION; TREATMENT RESPONSE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 35348841488     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1406.033     Document Type: Conference Paper

References (30)

1. AMPEL, N.M. 2001. Coccidioidomycosis among persons with human immunodeficiency virus infection in the era of highly active antiretroviral therapy (HAART). Semin. Respir. Infect. 16: 257-262.
2. AMPEL, N.M. 2005. Coccidioidomycosis in persons infected with HIV type 1. Clin. Infect. Dis. 41: 1174-1178.
3. AMPEL, N.M., C.L. DOLS & J.N. GALGIANI. 1993. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am. J. Med. 94: 235-240.
4. GALGIANI, J.N., A. CATANZARO, G.A. CLOUD, et al. 2000. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann. Intern. Med. 133: 676-686.
5. DRUTZ, D.J. & CATANZARO A. 1978. Coccidioidomycosis. Part I. Am. Rev. Respir. Dis. 117: 559-585.
6. ABRAMS, D.I., M. ROBIA, W. BLUMENFELD, et al. 1984. Disseminated coccidioidomycosis in AIDS. N. Engl. J. Med. 310: 986-987.
7. HERNANDEZ, J.L., S. ECHEVARRIA, A. GARCIA- VALTUILLE, et al. 1997. Atypical coccidioidomycosis in an AIDS patient successfully treated with fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 16: 592-594.
8. BRONNIMANN, D.A., R.D. ADAM, J.N. GALGIANI, et al. 1987. Coccidioidomycosis in the acquired immunodeficiency syndrome. Ann. Intern. Med. 106: 372-379.
9. FISH, D.G., N.M. AMPEL, J.N. GALGIANI, et al. 1990. Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore) 69: 384-391.
10. SINGH, V.R., D.K. SMITH, J. LAWERENCE, et al. 1996. Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution. Clin. Infect. Dis. 23: 563-568.
11. JONES, J.L., P.L. FLEMING, C.A. CIESIELSKI, et al. 1995. Coccidioidomycosis among persons with AIDS in the United States. J. Infect. Dis. 171: 961-966.
12. KAPLAN, J.E., D. HANSON, DWORKIN M.S. et al. 2000. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 30 (Suppl. 1): S5-S14.
13. PALELLA, F.J., JR., K.M. DELANEY, A.C. MOORMAN, et al. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338: 853-860.
14. WOODS, C.W., C. MCRILL, B.D. PLIKAYTIS, et al. 2000. Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: incidence, risk factors, and prevention. J. Infect. Dis. 181: 1428-1434.
15. CARMICHAEL, J.K. 2006. Coccidioidomycosis in HIV-infected persons. Clin. Infect. Dis. 42: 1059; author reply -60.
16. ARGUINCHONA, H.L., N.M. AMPEL, C.L. DOLS, et al. 1995. Persistent coccidioidal seropositivity without clinical evidence of active coccidioidomycosis in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 20: 1281-1285.
17. BLAIR, J.E., B. COAKLEY, A.C. SANTELLI, et al. 2006. Serologic testing for symptomatic coccidioidomycosis in immunocompetent and immunosuppressed hosts. Mycopathologia. 162: 317-324.
18. ANTONISKIS, D., R.A. LARSEN, B. AKIL, et al. 1990. Seronegative disseminated coccidioidomycosis in patients with HIV infection. AIDS 4: 691-693.
19. PAPPAGIANIS, D. 2001. Serologic studies in coccidioidomycosis. Semin. Respir. Infect. 16: 242-250.
20. GALGIANI, J.N., N.M. AMPEL, J.E. BLAIR, et al. 2005. Coccidioidomycosis. Clin. Infect. Dis. 41: 1217-1223.
21. DEWSNUP, D.H., J.N. GALGIANI, J.R. GRAYBILL, et al. 1996. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann. Intern. Med. 124: 305-310.
22. AMPEL, N.M. 1999. Delayed-type hypersensitivity, in vitro T-cell responsiveness and risk of active coccidioidomycosis among HIV-infected patients living in the coccidioidal endemic area. Med. Mycol. 37: 245-250.
23. WINSTON, A. & M. BOFFITO. 2005. The management of HIV-1 protease inhibitor pharmacokinetic interactions. J Antimicrob Chemother. 56: 1-5.
24. DE WIT, S., M. DEBIER, M. DE SMET, et al. 1998. Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 42: 223-227.
25. CATO, A., 3RD, G. CAO, A. HSU, et al. 1997. Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. Drug Metab. Dispos. 25: 1104-1106.
26. KOKS, C.H., K.M. CROMMENTUYN, R.M. HOETELMANS, et al. 2001. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. Br. J. Clin. Pharmacol. 51: 631-635.
27. CROMMENTUYN, K.M., J.W. MULDER, R.W. SPARIDANS, et al. 2004. Drug - drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis. Clin. Infect. Dis. 38: e73-e75.
28. MIKUS, G., V. SCHOWEL, M. DRZEWINSKA, et al. 2006. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin. Pharmacol. Ther. 80: 126-135.
29. MA, Q., O.O. OKUSANYA, P.F. SMITH, et al. 2005. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin. Drug Metab. Toxicol. 1: 473-485.
30. THEURETZBACHER, U., F. IHLE, & H. DERENDORF. 2006. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 45: 649-663.